GB202010652D0 - Anti-tau antibodies - Google Patents

Anti-tau antibodies

Info

Publication number
GB202010652D0
GB202010652D0 GBGB2010652.2A GB202010652A GB202010652D0 GB 202010652 D0 GB202010652 D0 GB 202010652D0 GB 202010652 A GB202010652 A GB 202010652A GB 202010652 D0 GB202010652 D0 GB 202010652D0
Authority
GB
United Kingdom
Prior art keywords
tau antibodies
tau
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2010652.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Priority to GBGB2010652.2A priority Critical patent/GB202010652D0/en
Publication of GB202010652D0 publication Critical patent/GB202010652D0/en
Priority to US18/004,772 priority patent/US12624096B2/en
Priority to PCT/EP2021/069160 priority patent/WO2022008719A1/en
Priority to CN202180062368.9A priority patent/CN116194479B/zh
Priority to JP2023501609A priority patent/JP7796719B2/ja
Priority to EP21739721.5A priority patent/EP4178980A1/en
Priority to TW110125334A priority patent/TWI912331B/zh
Priority to CA3185175A priority patent/CA3185175A1/en
Priority to KR1020237003616A priority patent/KR20230038721A/ko
Priority to AU2021306653A priority patent/AU2021306653A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB2010652.2A 2020-07-10 2020-07-10 Anti-tau antibodies Ceased GB202010652D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
AU2021306653A AU2021306653A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies
JP2023501609A JP7796719B2 (ja) 2020-07-10 2021-07-09 抗タウ抗体
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies
CN202180062368.9A CN116194479B (zh) 2020-07-10 2021-07-09 抗tau抗体
US18/004,772 US12624096B2 (en) 2020-07-10 2021-07-09 Anti-tau antibodies and methods of use thereof
EP21739721.5A EP4178980A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies
TW110125334A TWI912331B (zh) 2020-07-10 2021-07-09 抗tau抗體
CA3185175A CA3185175A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies
KR1020237003616A KR20230038721A (ko) 2020-07-10 2021-07-09 항-tau 항체

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies

Publications (1)

Publication Number Publication Date
GB202010652D0 true GB202010652D0 (en) 2020-08-26

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2010652.2A Ceased GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies

Country Status (10)

Country Link
US (1) US12624096B2 (enExample)
EP (1) EP4178980A1 (enExample)
JP (1) JP7796719B2 (enExample)
KR (1) KR20230038721A (enExample)
CN (1) CN116194479B (enExample)
AU (1) AU2021306653A1 (enExample)
CA (1) CA3185175A1 (enExample)
GB (1) GB202010652D0 (enExample)
TW (1) TWI912331B (enExample)
WO (1) WO2022008719A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
KR101231777B1 (ko) 2010-11-25 2013-02-08 부산대학교 산학협력단 ＧＳＫ３β 저해를 통한 타우 과인산화 저해제 탐색 방법
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN117205311A (zh) * 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
CN120305401A (zh) * 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Also Published As

Publication number Publication date
US20230257452A1 (en) 2023-08-17
EP4178980A1 (en) 2023-05-17
CN116194479B (zh) 2026-05-22
CN116194479A (zh) 2023-05-30
KR20230038721A (ko) 2023-03-21
WO2022008719A1 (en) 2022-01-13
US12624096B2 (en) 2026-05-12
JP7796719B2 (ja) 2026-01-09
TWI912331B (zh) 2026-01-21
TW202214686A (zh) 2022-04-16
CA3185175A1 (en) 2022-01-13
JP2023533768A (ja) 2023-08-04
AU2021306653A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
SI3872091T1 (sl) Protitelesa proti SARS-COV-2
IL308741A (en) Anti-SIRP-alpha antibodies
PT4214240T (pt) Anticorpos anti-ccr8
GB202105110D0 (en) Anti-CD73 antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
ZA202209699B (en) Novel antibodies
EP4377358A4 (en) NEW ANTI-SIRPA ANTIBODIES
GB202014851D0 (en) SARS-COV-2 antibodies
GB202008022D0 (en) Antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202207698D0 (en) Antibodies
GB202204159D0 (en) Antibodies
GB202102227D0 (en) Antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies
GB202107517D0 (en) Antibodies
GB202104128D0 (en) Antibodies
GB202103388D0 (en) Antibodies
GB202102401D0 (en) Antibodies
IL312391A (en) New anti-IL-36R antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)